In eight days, the FDA could approve the first new smoking cessation drug in 20 years. That is the timeline facing cytisinicline, a plant-based alkaloid developed by Achieve Life Sciences that has completed two successful Phase 3 trials and whose regulatory review concludes with a PDUFA-targeted action date of June 20, 2026.
If approved, cytisinicline would join a short list of FDA-approved pharmacological aids for smoking cessation — bupropion (Wellbutrin/Zyban, approved in 1997 for depression and smoking in 1997 and 2000) and varenicline (Chantix, approved in 2006). That is effectively 20 years during which the FDA-approved toolkit for helping Americans quit tobacco has not grown, even as approximately 28 million adults continue to smoke and tobacco kills nearly half a million Americans every year, costing the U.S. economy an estimated $600 billion annually.
Cytisinicline's mechanism is rooted in a plant that has been used in Eastern European folk medicine as a smoking deterrent for decades. It is an alkaloid derived from the golden rain tree (Laburnum anagyroides) that selectively binds to nicotinic acetylcholine receptors — the same receptors targeted by nicotine and by varenicline. By partially activating these receptors, cytisinicline reduces nicotine cravings and withdrawal symptoms while simultaneously providing less reward from smoking, making cigarettes less satisfying. The pharmacological concept is similar to varenicline (Chantix), but the molecular structure is different — and critically, the side-effect profile appears more favorable.
What the Phase 3 Trials Showed
The FDA's review is supported by data from two pivotal Phase 3 clinical trials. ORCA-2 enrolled 810 adult smokers randomly assigned to cytisinicline 3 mg three times daily for 12 weeks, a 6-week cytisinicline plus 6-week placebo regimen, or 12 weeks of placebo. ORCA-3 enrolled 792 adult smokers in the same design. In both trials, cytisinicline demonstrated statistically significant and clinically meaningful improvements in smoking abstinence rates compared to placebo at the end of treatment and at follow-up.
Cytisinicline's key differentiator from varenicline — the most effective currently approved quit-smoking medication — is its side-effect profile. Varenicline's efficacy is well-established, but the drug carries a meaningful incidence of nausea, vivid dreams, and — before its boxed warning was removed in 2021 — had been associated with neuropsychiatric concerns that made many physicians hesitant to prescribe it. Clinical research to date suggests cytisinicline produces a meaningfully lower burden of gastrointestinal and psychiatric side effects.
"Smoking is the leading cause of preventable death and disease, claiming the lives of nearly half a million Americans each year," said Rick Stewart, CEO of Achieve Life Sciences. "The FDA's acceptance of our NDA filing underscores nicotine dependence as an important public health need that demands action."
Beyond smoking, cytisinicline has received FDA Breakthrough Therapy designation for vaping cessation — a separate indication for which there is currently no approved pharmacotherapy. A Phase 2 study was completed, and an end-of-Phase 2 meeting with the FDA was conducted, positioning cytisinicline for a potential future NDA for vaping cessation if Phase 3 data support it. The vaping cessation angle is particularly significant in 2026, when youth e-cigarette use remains a major public health concern, and clinicians have no approved pharmacotherapy to offer adolescents or adults who want to quit vaping.
What an Approval Would Mean for Public Health
Twenty million quit attempts are made by American smokers every year. Fewer than 10 percent succeed without support. With behavioral counseling and pharmacotherapy combined, success rates reach 25 to 30 percent. The presence of an additional pharmacological option — particularly one with a more favorable side-effect profile than existing drugs — gives prescribers more flexibility to match treatment to individual patient preferences and risk factors, and increases the overall likelihood that more people can successfully quit.
An FDA approval on June 20, 2026 would not instantly solve the smoking epidemic. But it would represent the most significant expansion of the smoking cessation toolkit in a generation, and mark the first time that a plant-derived folk remedy has been refined, clinically validated, and approved by the U.S. regulatory system as a serious therapeutic option for one of the country's most costly preventable health problems.
Frequently Asked Questions
Q: What is cytisinicline, and when might it be approved?
A: Cytisinicline is a plant-based alkaloid for smoking cessation. Its PDUFA targeted FDA decision date is June 20, 2026. If approved, it would be the first new quit-smoking drug in 20 years.
Q: How does cytisinicline work?
A: It partially activates nicotinic acetylcholine receptors, reducing nicotine cravings and withdrawal symptoms while making smoking less rewarding — similar in mechanism to varenicline (Chantix) but with a different molecular structure.
Q: How effective is cytisinicline compared to existing drugs?
A: Phase 3 ORCA-2 and ORCA-3 trials showed statistically significantly higher quit rates compared to placebo. Direct head-to-head comparisons with varenicline are limited, but cytisinicline appears to have a more favorable side-effect profile.
Q: What are the side effects of cytisinicline?
A: Available data suggest fewer gastrointestinal and neuropsychiatric side effects compared to varenicline. The safety database includes over 400 participants with at least 6 months of exposure, with no new safety concerns identified by the Data Safety Monitoring Committee.
Q: Could cytisinicline help with vaping cessation, too?
A: Cytisinicline has received FDA Breakthrough Therapy designation for vaping cessation, a separate indication for which there is currently no approved pharmacotherapy. Phase 3 trials for vaping cessation are being planned.
